NEW YORK, NY — October 10, 2025 — Leads & Copy — Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that Prof. Dr. Timo Grimmer, MD, a member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX®2-73-AD-004 study, presented “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” at the 35th Alzheimer Europe Conference.
The presentation is accessible in the Investors section of the company’s website.
Anavex Life Sciences Corp. is focused on developing treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer’s, Parkinson’s, schizophrenia, Rett syndrome, and other CNS diseases. The lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed clinical trials for Alzheimer’s and Parkinson’s diseases, and Rett syndrome. ANAVEX®3-71 targets SIGMAR1 and M1 muscarinic receptors and has shown disease-modifying activity against Alzheimer’s hallmarks in preclinical trials.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
Contact:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
Source: Anavex Life Sciences Corp.
